Vetter Monica L, Hitchcock Peter F
Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, UT, USA.
Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, UT, USA ; Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
Transl Vis Sci Technol. 2017 Mar 15;6(2):5. doi: 10.1167/tvst.6.2.5. eCollection 2017 Mar.
This report emerges from a workshop convened by the National Eye Institute (NEI) as part of the "Audacious Goals Initiative" (AGI). The workshop addressed the replacement of retinal ganglion cells (RGCs) from exogenous and endogenous sources, and sought to identify the gaps in our knowledge and barriers to progress in devising cellular replacement therapies for diseases where RGCs die. Here, we briefly review relevant literature regarding common diseases associated with RGC death, the genesis of RGCs in vivo, strategies for generating transplantable RGCs in vitro, and potential endogenous cellular sources to regenerate these cells. These topics provided the clinical and scientific context for the discussion among the workshop participants and are relevant to efforts that may lead to therapeutic approaches for replacing RGCs. This report also summarizes the content of the workshop discussion, which focused on: (1) cell sources for RGC replacement and regeneration, (2) optimizing integration, survival, and synaptogenesis of new RGCs, and (3) approaches for assessing the outcomes of RGC replacement therapies. We conclude this report with a summary of recommendations, based on the workshop discussions, which may guide vision scientists seeking to develop therapies for replacing RGCs in humans.
本报告源自美国国立眼科研究所(NEI)召开的一次研讨会,该研讨会是“大胆目标倡议”(AGI)的一部分。此次研讨会探讨了从外源性和内源性来源替换视网膜神经节细胞(RGCs)的问题,并试图找出我们在设计针对RGCs死亡疾病的细胞替代疗法方面的知识空白和进展障碍。在此,我们简要回顾有关与RGCs死亡相关常见疾病、RGCs在体内的起源、体外生成可移植RGCs的策略以及再生这些细胞的潜在内源性细胞来源的相关文献。这些主题为研讨会参与者之间的讨论提供了临床和科学背景,并且与可能导致RGCs替代治疗方法的研究工作相关。本报告还总结了研讨会讨论的内容,重点关注:(1)RGCs替代和再生的细胞来源;(2)优化新RGCs的整合、存活和突触形成;(3)评估RGCs替代疗法结果的方法。我们根据研讨会讨论内容总结了建议,以此结束本报告,这些建议可能会指导视觉科学家寻求开发用于人类RGCs替代的疗法。